Drug Discovery & Pharmaceuticals

RSS

Insilico Medicine to showcase AI-driven drug breakthroughs at BIO 2026 International Convention

Insilico Medicine will attend the BIO 2026 International Convention, held from June 22 to 25 at the San Diego Convention Center.

18 Jun 2026

Deep learning identifies novel compounds against antibiotic-resistant gonorrhea

With tens of millions of annual cases, gonorrhea is the second most frequently reported sexually transmitted infection (STI). Alone in the U.S., over 600,000 cases are reported each year.

17 Jun 2026

Purdue develops next-generation platform to accelerate cancer drug discovery

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

16 Jun 2026

Machine learning identifies natural compound to treat lung disease

A new study published in Engineering has combined machine learning (ML) and experimental validation to identify dihydromyricetin (DHM), a natural flavonoid, as a potent inhibitor of the TGF-β/ALK5 signaling cascade with therapeutic potential for idiopathic pulmonary fibrosis (IPF).

16 Jun 2026

UVA joins SPARK GLOBAL initiative to accelerate the development of new medicines

The University of Virginia has joined the SPARK GLOBAL initiative to accelerate the development of new medicines and find solutions for the most urgent and complex healthcare challenges of our time.

15 Jun 2026

Urine drug test may boost adherence to blood pressure medications

The largest ever UK trial of a urine test used across the NHS to spot when patients skip their medication has shown it may improve adherence to treatment.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

Single-dose vaccine provides complete protection against Andes hantavirus

In a study published in The Lancet, researchers at The University of Texas Medical Branch (UTMB) report the development of new vaccines that, in animal testing, provided full protection against the deadly Andes hantavirus after a single dose.

11 Jun 2026

AI breakthrough accelerates molecular simulations for drug discovery

A new AI model has become so good at predicting how molecules evolve over time that, in the future, it could speed up the costly and time-consuming process of testing new drugs.

11 Jun 2026

Structure of the Argonaute maturation complex guides RNA therapeutic design

RNA therapeutics have emerged as one of the most promising new classes of medicines. Eight small interfering RNA (siRNA) drugs have already been approved worldwide for the treatment of genetic diseases, yet scientists have not fully understood one of the most fundamental steps underlying their function: how Argonaute, the core protein responsible for gene silencing, becomes activated.

11 Jun 2026

First-in-the-world gene therapy delivers missing gene directly to infant’s brain, marking historic milestone in precision medicine

An eight-month-old baby from Israel has become the first human ever to receive an experimental gene therapy designed to replace a missing gene responsible for a devastating neurological disease that until now offered no hope of survival.

11 Jun 2026

Automated self-driving labs accelerate the search for new medicines

The Acceleration Consortium (AC) at the University of Toronto and the Structural Genomics Consortium (SGC) announced today a formalized partnership to help tackle a persistent challenge in biomedicine and early drug discovery: the development of bioactive molecules with drug-like properties, advancing our understanding of human health and disease and jump-starting new drug discovery programs.

10 Jun 2026

Critical Path Institute opens registration for 2026 Global Impact Conference

Critical Path Institute (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington Marriott at Metro Center in Washington, D.C.

10 Jun 2026

New antibiotic from soil bacteria targets drug-resistant superbugs

Scientists at the University of Illinois Chicago have discovered a new antibiotic that may be a bulwark in the fight against drug-resistant superbugs, according to new research published in Nature.

9 Jun 2026

Realistic cellular conditions revive previously dismissed drug candidates

A drug once dismissed as ineffective suddenly worked - when scientists tested it under more realistic conditions that mimic the human body.

9 Jun 2026

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Professor Heddle's insights on nanobiology and AI highlight their potential to innovate drug delivery and vaccine development, addressing critical health needs.

9 Jun 2026

Webinar - Modality agnostic drug discovery strategies for data sparse targets: Lessons learned from Avammune & Cresset, hosted by Visioneers

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to trial-stage candidates in this space.

From Cresset 4 Jun 2026

Study potentially opens a new route to more selective cancer drug design

Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs.

3 Jun 2026

New antibiotic kills drug-resistant bacteria by targeting a previously unknown vulnerability

Researchers at McMaster University have discovered a new antibiotic that kills some of the world's most dangerous and drug-resistant bacteria - and does so by targeting a previously unknown vulnerability, opening the door to an entirely new class of treatments.

3 Jun 2026

ELRIG unveils keynote speakers for Drug Discovery 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speaker program for Drug Discovery 2026.

From ELRIG (UK) Ltd. 3 Jun 2026